

**12th Meeting
(Hybrid)**

**Working Group: Open ———
Consultation**



OPEN CONSULTATION

Industry active
participation

Importance of Industry Shaping
of Regulations

*One standard, one test, accepted everywhere
for any medical technology scope*

– EXECUTIVE COMMITTEE



Open Consultation WG



Main Objective: provide support to stakeholders on how to gain **visibility and/or address** Open Consultations, seeking harmonization with international standards and following GRP.




Sources of information - available -
updated – filtered - relevant



Scope: different scenarios are to be
addressed



**Quality Feedback for Quality
discussions with Regulators**




Different scenarios in different
countries : Subsidiary / distributor/
consultant / Trade Association



Avoid Company biases - Law
hierarchies - GRP

ROADMAP



May
2024



Open Consultation WG Survey



Survey Goal:
screening of current
landscape across
the region

Addressed Topics:



- Familiar with OC?
- Visibility-Sources?
- Usual Participation
- OC Period
- OC Transparency
- Method to publicize
- Method to gain visibility
- HA responsiveness to feedback

The screenshot shows a survey form with the following content:

REGULATORY CONVERGENCE
MEDICAL TECHNOLOGY SECTOR

Survey Open Consultation Working Group- Current Landscape

Dear RA colleagues,

The final goal of this Open Consultation Working Group (IACRC) is to provide support to stakeholders on how to have visibility and/or address Open Consultations, seeking harmonization with international standards and following GRP.

But as a first step we need to identify needs and priorities across countries.

This survey aims to perform a screening of current landscape across the region and your reply is much appreciated for developing useful tools to support the industry in shaping the Regulations impacting Medical Devices!

Thanks in advance for your reply!

1- Which country are you representing?

[Text input field]

2-Are you familiar with the public consultation processes carried out by the health authorities in your country regarding Medical Device Regulations?

- ☐ Yes, active participation
- ☐ Quite familiar
- ☐ Somewhat familiar
- ☐ Little
- ☐ Not at all

3-On average, how long does a public consultation process typically last?

- ☐ 0-30 days
- ☐ 31-60 days
- ☐ 61-90 days
- ☐ other

4-Are the public consultation processes considered transparent and easily accessible to stakeholders in your country? (Please rate on a scale of 1-5, with 1 being very poor and 5 being excellent)

1	2	3	4	5
---	---	---	---	---

0 Very Satisfied

5- Which methods Regulator use to publicize these consultations?



Open Consultation WG Survey



Información general sobre respuestas Activo

Respuestas

45



Tiempo promedio

03:32



Duración

138 Días






Open Consultation WG

Survey- OC Industry Participation



3. Do you usually participate/contribute to address draft regulations in:

● Domestic Open Consultations	26
● International Open Consultations	1
● Domestic and International Open Consultations	15
● No	3





Open Consultation WG Survey- Results- Visibility



Regulator
Publication

Board of Directors Regulator website trade associationPE LinkedIn official diary
social medias trade websitesOfficial trade associationBR
official gazettePY email Official journal trade Association public meetings
official gazetteUS regular meetings step by step regulatory process

Industry
Visibility

emails both from members Health Canada periodic checksSV
social mediaUY periodic checksUS periodic checksBO
periodic checksPE + trade association Local trade
periodic checksCR periodic checks trade association+ official intel tool
newspaper publication Official newspaper consultant eping periodic checksBR




Open Consultation WG Survey- HA Responsiveness




12. Are the health authorities responsive to the feedback received during the public consultation processes? (Please rate on a scale of 1-4, with 1 being very low and 4 being very high)

1 2 3 4 Not applicable



Nov
2024

Open Consultation WG Toolkit



BECOME AWARE

DRAFT INITIAL ASSESSMENT

PREPARE COMMENTS

SUBMIT & FOLLOW-UP

Active/ Passive search:
Subscribe to email
alerts from e-ping,
search national
portals.

[See instructions for e-Ping subscription & list of portals per country. ATTACHMENT 1.](#)

DRAFT

- a. Is the issuing country signatory to Good Regulatory Practices agreements? Is the draft notified via e-ping?
- b. Is the deadline for commenting aligned with GRP? If not, ask for an extension.
- c. Is there an overlap with other domestic regulations?
- d. Is there an overlap with other international regulations?
- e. Is the regulation necessary ?
- f. Is reliance or recognition possible?
- g. Is it possible to implement?
- h. What's the cost of implementing? *See impact assessment & include relevant stakeholders*
- i. What is the benefit of implementing?
- j. Is an impact assessment from the Health Authority available? *See HA obligations-Refer Literature ATTACHMENT 2-*
- k. Is the implementation timeline feasible?
- l. Map stakeholders to participate in the assessment & include their perspective.
- m. Recognize or create an effective communication channel with the authorities to guarantee engagement in future discussions.
- n. Set a follow-up strategy after comments submission

- a. Always refer comments/suggestions to international or domestic regulation.
- b. Structure your comments clearly and objectively, highlighting the most relevant points. [ATTACHMENT 3](#)
- c. Prioritize the mitigation of risks, effects, and negative impacts identified.
- d. Seek alignment with international standards and practices in the same or similar sectors.
- e. List the positive and negative impacts perceived with the draft in the Public Consultation and summarize the proposed contributions to minimize negative impacts and highlight the positive impacts expected by incorporating the proposed contributions into the regulation.

After the contribution proposal is finalized, review the initial assessment.

-Ensure compliance with the contribution format determined by the HA promoting the Public Consultation and adherence to the deadline set by the HA and accepted submission channels by the HA.
- Seek HA PoC to discuss feedback on OC.
- Grant feedback is processed and replied by HA

FOLLOWING UP POST-PUBLIC CONSULTATION

Follow up with the regulatory body and explore all available social and sectoral participation options to emphasize the contributions and their importance to society or the sector.

MONITOR THE ADHERENCE TO GRP





Toolkit Attachments



	Supporting STAGE	ATTACHMENT
Attachment 1	Step 1 - BECOME AWARE	e-Ping Subscription Tutorial & List of Regulators' webpages (links) by country
Attachment 2	Step 2 - DRAFT INITIAL ASSESSMENT	Reference background Literature on Good Regulatory Practices OC to refer /consult.
Attachment 3	Step 3 - PREPARE COMMENTS	AdvaMed Table Format example & Directions on how to complete this Table to submit comments to Regulators.

Annex I.a - List of Regulators' webpages & Links to Open Consultation publication sites


<https://www.interamericancoalition-medtech.org/regulatory-convergence/quick-links/medical-device-regulatory-authorities/>

Country	Regulator	Webpage
ARG	ANMAT	https://opinionpublica.anmat.gob.ar/Home
MEX	MEXICO	https://www.cofemersimir.gob.mx
BRA	BRAZIL	<u>Consultas Públicas – Anvisa</u> https://antigo.anvisa.gov.br/consultas-publicas#/
..		
..		

Annex I- b - Tutorial e-ping Subscription

1- Create an Account: <https://epingalert.org/en/Account/Registration>

2. Select products and markets of interest to receive alerts



Product(s)
medical devices

HS code(s) ⓘ
Start typing product names or codes and the corresponding options will appear ▼

ICS code(s) ⓘ
Start typing product names or codes and the corresponding options will appear ▼

Export markets (notifying Members)
All Members ▼


Area
SPS ▼

Receive an email alert if new notifications match selected criteria:

☒ Daily ☐ Weekly ☐ No emails

Annex II – Reference Literature – GRP on Open Consultations

High Level Checklist to follow in each Phase



Phases

- Prior to start / During planning process
- During the regulatory process
- After the regulatory process

Annex II – Reference Literature – GRP on Open Consultations

Practical Checklist item by item

GOOD REGULATORY PRACTICES CHECKLIST TECHNICAL REGULATIONS Section I. Prior to the start of the regulatory process / During the planning process										
DISCIPLINE TYPE	OBLIGATION	LEGAL GROUND						WAS IT FULFILLED?		
		USMCA Chapters 11, 28	CPTPP Chapters 8 y 25	PA Chapters 7, 15 BIS	TBT Agreement	LGMR	LIC	Yes	No	N/A
1. Technical Regulations - National Treatment	1.1 Does the proposed technical regulation establish the characteristics of a product or the processes and production methods related to them, including the applicable administrative provisions?	11.1	8.1.1	7.3	Annex 1, paragraph 1	N/A	4 subsection XVI			
	1.2 Does the proposed technical regulation establish terminology, symbols, packaging, marking or labeling requirements applicable to a product, process, or production method, or does it deal exclusively with them?	11.1	8.1.1	7.3	Annex 1, paragraph 1	N/A	4 subsection XVI			
	1.3 Is the instrument referred to in questions 1.1 or 1.2 mandatory?	11.1	8.1.1	7.3	Annex 1, paragraph 1	N/A	4 subsection XVI			
	1.4 Did COFEPRIS ensure that the technical regulation provides imported products from any of Mexico's trading partners no less favorable treatment than that accorded to similar products of national origin?	11.3.1.a	8.4.1	7.3	2.1	8, subsection III	12 (fourth paragraph)			
	1.5 In the technical regulations that have as scope the prescription of the products, did COFEPRIS define such products based on the properties of use and application of the products?	N/A	N/A	7.3	2.8	N/A	12 (fifth paragraph)			
	1.6 In the technical regulations that have as scope the prescription of products, did COFEPRIS avoid defining products based on their design or descriptive characteristics?	N/A	N/A	7.3	2.8	N/A	12 (fifth paragraph)			
2 Technical Regulations - Preparation	2.1 Did COFEPRIS carry out an adequate assessment of the technical regulation, including a regulatory impact analysis of the potential impacts of the technical regulation?	11.5.1.a	N/A	N/A	N/A	2 subsection XV, 71	34 subsection X			
	2.2 Did COFEPRIS carry out an evaluation of alternative measures that could be applied instead of the technical regulation?	11.5.1.b	N/A	N/A	2.2	69 subsection II	32 subsection I			

Annex III – Formatting & Directions How to Submit Comments to HA

- Then assess item by item, each sentence in the Regulation following this table format below.

Instructions:

- ✓ Strikethrough the text to be deleted and in ~~red-color~~
- ✓ Underline the new text to be added and in blue color
- ✓ Provide rationale for this change indicating GRP- Regulation to be aligned with - etc

Particular Comments

<u>Statement/Dice</u>	<u>Should be replaced by/Debe decir</u>	<u>Rationale / Justificación</u>
Artículo 1. El presente Acuerdo tiene por objeto establecer las disposiciones que debe observar la Comisión Federal para la Protección contra Riesgos Sanitarios para utilizar y reconocer las decisiones de otras Autoridades Reguladoras de Referencia y del Programa de Precalificación de Medicamentos de la Organización Mundial de la Salud para el registro sanitario y el ciclo de vida de los insumos para la salud.	Artículo 1. El presente Acuerdo tiene por objeto establecer las disposiciones que debe observar la Comisión Federal para la Protección contra Riesgos Sanitarios para utilizar y reconocer las decisiones de otras Autoridades Reguladoras de Referencia y del Programa de Precalificación de Medicamentos, <u>de Dispositivos Médicos y de Reactivos de Diagnóstico in vitro</u> , de la Organización Mundial de la Salud para el registro sanitario y el ciclo de vida de los insumos para la salud.	Se propone agregar el Programa de Precalificación de la OMS para Dispositivos Médicos y Reactivos de Diagnóstico <i>in vitro</i> .



THANK YOU

MAGDALENA FERRARI DEL SEL

RA LEAD - POLICY SPECIALIST
JOHNSON & JOHNSON MEDTECH

mferrar8@its.jnj.com

ROBERTA MELE MAZZA

CADIEM ROCHE DIAGNOSTICS

SANDRA LIGIA GONZÁLEZ

Executive Secretary

LETICIA FONSECA

Executive Sub-Secretary